No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disp...
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith copies of notice ...
Divi's Laboratories Limited has informed the Exchange regarding 'Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirement...
Divi's Laboratories Limited has informed the Exchange regarding 'Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirement...
Divis Laboratories Ltd has informed BSE that a meeting of Board of Directors of the Company is scheduled to be held on May 26, 2018, inter-alia, to co...
Notice is hereby given that a meeting of Board of Directors of the Company is scheduled to be held on Saturday, the 26th day of May 2018, inter-alia, ...
Divi's Laboratories Limited has informed the Exchange regarding 'Divi?s Laboratories hereby announces that its Unit-I at Choutuppal, Telangana State h...
We enclose herewith the revised Compliance Certificate under Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2...
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disp...
Please find enclosed Compliance Certificate as required under Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, ...
Notice is hereby given that a meeting of Board of Directors of the Company is scheduled to be held on Saturday, the 27th day of January 2018 to consid...
In compliance with Regulation 13 (3) of SEBI (LODR) Regulations, 2015, please find below the statement of investors complaints for the quarter ended 3...
We had earlier informed the Exchanges vide our letter of 2nd November, 2017 that the US-FDA will be lifting the Import Alert 66-40 imposed on the comp...
Divi's Laboratories Limited has informed the Exchange regarding 'We had earlier informed the Exchanges vide our letter of 2nd November, 2017 that the ...
Further to our letter dated 2nd November, 2017, Divis Laboratories has been informed by the US-FDA that the Agency has completed evaluation of the Com...
Divi's Laboratories Limited has informed the Exchange regarding 'Further to our letter dated 2nd November, 2017, Divi?s Laboratories has been informed...
Divis Laboratories has been informed by the US-FDA that it will be lifting the Import Alert 66-40 and moving to close out the Warning letter issued to...